Drug – bio-affecting and body treating compositions – Effervescent or pressurized fluid containing – Organic pressurized fluid
Patent
1995-05-02
1997-07-29
Bawa, Raj
Drug, bio-affecting and body treating compositions
Effervescent or pressurized fluid containing
Organic pressurized fluid
424 46, 514 51, A61K 912
Patent
active
056519575
ABSTRACT:
A method of facilitating the clearance of retained pulmonary secretions in a subject using lantibiotics is disclosed. The method comprises administering to the lungs of the subject an effective amount of a lantibiotic. The lantibiotic is preferably administered by topically applying it to the respiratory epithelia, such as by generating an aerosol thereof which is then inhaled by the subject. A preferred lantibiotic for carrying out the present invention is duramycin. The method may be used in treating disorders such as cystic fibrosis, chronic bronchitis, and asthma. Also disclosed is a method of combatting tuberculosis comprising administering a lantibiotic to a subject in need of such treatment.
REFERENCES:
patent: 4501729 (1985-02-01), Boucher et al.
patent: 5162348 (1992-11-01), Glass
patent: 5292498 (1994-03-01), Boucher, Jr.
patent: 5318778 (1994-06-01), Schmucker et al.
patent: 5384128 (1995-01-01), Meezan et al.
C.S. Stock; Breathing Easier, Endeavors X No. 1, (1992).
D.K. Stone et al; Inhibition of Clathrin-coated Vesicle Acidification by Duramycin, J. Biol. Chem 259, pp. 2701-2703 (1984).
M.M. Clouthier et al.; Duramicin Enhances Chloride Change Activity in Cystic Fibrosis Nasal Epithelial Cells, Pediatric Pulmonology Supplement 2, (1988).
M.M. Clouthier et al; Stimulation of Chloride Secretion by Duramycin, Pediatric Pulmonology Supplement 1. (1987).
M.M. Clouthier et al; Duramycin Increases Intracellular Calcium, Pediatric Pulmonology Supplement 4 (1989).
M.M. Cloutier et al; Duramycin enhances chloride secretion in airway epithelium, The American Physiological Society, p. C450 (1990).
M. Roberts et al; Stimulation of Sodium Transport by Duramycin in Cultured Human Colonic Epithelia, The Journal of Pharmacology and Experimental Therapeutics 259 No. 3, pp. 1050-1058 (1991).
G.J. Annas; Control of Tuberculosis--The Law and the Public's Health, The New England Journal of Medicine 328 No. 8, pp. 585-588 (1993).
T.R. Frieden et al; The Emergency of Drug-Resistant Tuberculosis in New York City; The New England Journal of Medicine 328 No. 8, pp. 521-532 (1993).
M. Barinaga; New Test Catches Drug-Resistant TB in the Spotlight, Science 260, pp. 750 (1993).
W.R. Jacobs, Jr et al; Rapid Assessment of Drug Susceptibilities of Mycabacterium tuberculosis by Means of Luciferase Reporter Phages; Science, 260 pp. 819-822 (1993).
A.T.R. Mattick et al; Further Observations on an Inhibitory Substance (NISIN) From Lactic Streptococci; The Lancet (ii), pp. 5-7 (1947).
A.C. Frazer et al; The Biological Effects of Food Additives I.--Nisin; J. Sci. Food Agric 13 pp. 33-42 (1962).
A. Hurst; Nisin; Advances in Applied Microbiology 27, pp. 85, 94-95 (1981).
G. Lung; Lantibiotics-Ribosomally Synthesized Biologically Active Polypeptides Containing Sulfide Bridges and .alpha.,.beta.-Didehydroamino Acids; Angew. Chem. Int. Ed. Engl. 30, pp. 1051-1068 (1991).
F. Hayashi et al; The Structure of PA48009: The Revised Structure of Duramycin; The Journal of Antibiotics XLIII No. 11, pp. 1421-1430 (1990).
A. Fredenhagen et al; Duramycins B and C, Two New Lanthionine Containing Antibiotics as Inhibitors of Phospholipase A.sub.2 Structural Revision of Duramycin and Cinnamycin, The Journal of Antibiotics XLIII No. 11, pp. 1403-1412 (1990).
I. Maclusky et al; Inhaled antibiotics in Cystic Fibrosis: Is There a Therapeutic effect?, J. Pediatr 108 No. 2, pp. 861-865 (1986).
M.A. Wall et al; Inhaled Antibiotics in Cystic Fibrosis; The Lancet, pp. 1325 (1983).
J.M. Littlewood et al; Aerosol Antibiotic Treatment in Cystic Fibrosis; Arch. Dis. Child (Eng) 68 No. 6, pp. 788-792 (Jun. 1993).
J. A. Bosso; Advances in the pharmacotherapy of cystic fibrosis, Journal of Clinical Pharmacy and Therapeutics 17, pp. 263-270 (1992).
R. Zabner and J. P. Quinn; Antimicrobials in Cystic Fibrosis: Emergency of Resistance and Implications for Treatment; Seminars in Respiratory Infections 7 No. 3, pp. 210-217 (1992).
R.C. Boucher; Drug Therapy in the 1990s What Can We Expect for Cystic Fibrosis?; Drugs 43 No. 4; pp. 431-439 (1992).
R.C. Cohn et al; In Vitro activity of Amiloride Combined with Toramycin Against Pseudomonas Isolates from Patients with Cystic Fibrosis; CA 108 (15): 128373q.
A. Malabarba et al; Synthesis and biological activity of some amide derivatives of the lantibiotic actagrdine, The Journal of Antibiotics, XLIII No. 9, Sep. 1990, pp. 1089-1097.
Boucher, Jr. Richard C.
Henke David C.
Molina y Vedia Luis Miguel
Stutts Monroe Jackson
Bawa Raj
Molichem Medicines, Inc.
LandOfFree
Method of treating retained pulmonary secretions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating retained pulmonary secretions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating retained pulmonary secretions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-631525